N🟁N

HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast

  //health-fitness.news-articles.net/content/2012/ .. -annual-healthcare-conference-to-be-webcast.html
  Published in Health and Fitness on Thursday, December 6th 2012 at 6:16 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to... -- FRAMINGHAM, Mass. and SYDNEY, Dec. 6, 2012 /PRNewswire/ --

FRAMINGHAM, Mass. and SYDNEY, Dec. 6, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: [ HTWR ] - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Oppenheimer 23^rd Annual Healthcare Conference at 10:00 a.m. EST on Thursday, December 13, 2012.  The conference is being held December 12-13 at the Waldorf-Astoria in New York City.

A live webcast of the Company's presentation at the conference will be available via a link provided at [ www.heartware.com ].  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare^® Ventricular Assist System features the HVAD^® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, and has received CE Marking in the European Union and has been used to treat patients in 27 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at [ www.heartware.com ].

HeartWare International, Inc. is a member of the Russell 2000^® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: [ ctaylor@heartwareinc.com ]
Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.